Sanofi Consumer Healthcare India Ltd
NSE: SANOFICONR BSE: 544250Pharma
Incorporated in 2023, Sanofi Consumer Healthcare India Ltd manufactures and trading of drugs & pharmaceutical products.[1]It is a division of Sanofi, a global pharmaceutical company, focusing on over-the-counter (OTC) and consumer healthcare products. [2]
₹4,795
52W: ₹3950 — ₹5954
PE 43.7 · Book ₹167 · +2771% vs bookMarket Cap₹11,044 Cr
Stock P/E43.7Price to Earnings
ROCE108%Return on Capital
ROE86.2%Return on Equity
Div. Yield1.13%Face Value ₹10
Strengths
- +Company is almost debt free.
- +Company is expected to give good quarter
- +Company has a good return on equity (ROE) track record: 3 Years ROE 83.6%
Weaknesses
- −Stock is trading at 28.7 times its book value
Shareholding Pattern
Promoters71.27%
FIIs2.76%
DIIs17.57%
Public8.41%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 60.4% | 60.4% | 60.4% | 60.4% | 71.27%▲10.9 | 71.27% | 71.27% | 71.27% |
| FIIs | 6.03% | 5.22%▼0.8 | 4.42%▼0.8 | 4.52%▲0.1 | 3.24%▼1.3 | 2.94%▼0.3 | 2.83%▼0.1 | 2.76%▼0.1 |
| DIIs | 22.6% | 23.83%▲1.2 | 25.35%▲1.5 | 25.48%▲0.1 | 16.89%▼8.6 | 17.21%▲0.3 | 17.33%▲0.1 | 17.57%▲0.2 |
| Public | 10.98% | 10.56%▼0.4 | 9.84%▼0.7 | 9.59%▼0.3 | 8.59%▼1.0 | 8.58%▼0.0 | 8.57%▼0.0 | 8.41%▼0.2 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 225 | 222 | 172 | 160 | 171 | 173 | 221 | 234 | 251 | 229 |
| Expenses | 135 | 140 | 109 | 97 | 109 | 109 | 151 | 149 | 161 | 140 |
| Operating Profit | 90 | 82 | 64 | 63 | 62 | 64 | 70 | 85 | 90 | 89 |
| OPM % | 40% | 37% | 37% | 39% | 36% | 37% | 32% | 36% | 36% | 39% |
| Net Profit | 68 | 63 | 29 | 45 | 44 | 50 | 61 | 63 | 66 | 68 |
| EPS ₹ | 0 | 0 | 12.59 | 19.54 | 19.24 | 21.71 | 26.36 | 27.31 | 28.87 | 29.44 |
AI Insights
Revenue Trend
TTM revenue at ₹935Cr, up 6.5% YoY. OPM at 36%.
Debt Position
Borrowings at ₹28Cr. Debt-to-equity ratio: 0.12x. Healthy balance sheet.
Institutional Flow
DIIs: 17.57% (-5.03pp change). FIIs: 2.76% (-3.27pp change). Promoters hold 71.27%.
Margin & Efficiency
ROCE improving from 0% (Dec 2023) to 0% (Dec 2025). Working capital days: 0.
Valuation
PE 43.7x with 108% ROCE. Price is 2771% above book value of ₹167. Dividend yield: 1.13%.
Recent Announcements
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 5 May
- Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors 30 Apr - Kalyaniwalla & Mistry LLP resigned as Sanofi Consumer Healthcare India’s statutory auditor effective 30 April 2026 over fee dispute.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Apr - Copy of Newspaper Publication of Unaudited Financial Result for the quarter ended 31st March 2026 is enclosed.
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 Apr - Sanofi Consumer Healthcare India reported Q1’26 revenue of ₹2,292 million and PAT of ₹678 million, up 33% and 36%.
- Results - Financial Results For March 31, 2026 28 Apr - Q4 FY26 unaudited results approved on 28 Apr 2026; revenue 2,292 million, profit 678 million.
- Financial Year 2024 from bse
- Financial Year 2024 from bse
- Transcript